Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Discloses 10 Percent Stake Held by Mazama

NEW YORK (GenomeWeb News) – Mazama Capital Management owns a 10 percent stake in Affymetrix’s Class A common stock, according to a filing with the US Securities and Exchange Commission today.
 
The Portland, Oregon-based investment advisory firm owned 6,783,041 shares of Affy’s common stock as of April 15.
 
As reported yesterday by GenomeWeb Daily News, Affy said in an SEC filing that Fidelity Management & Research now owns 5,050,490 shares of the firm’s common stock, which represents a nearly 7.3 percent stake in Affy. Of that total amount, the Fidelity Growth Company Fund owns 4,403,190 shares, representing a stake of 6.34 percent in Affy as of April 30.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.